Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody Ashby

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Haematologica|February 22, 2020
Differential RNA splicing as a potentially important driver mechanism in multiple myelomaMichael A Bauer, Cody Ashby, Christopher Wardell, et al.
Life Science Alliance|February 24, 2026
Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulationNoemi Garcia Garcia, Thanh Ha Vy Nguyen, Dane Richey, et al.
BMC Bioinformatics|October 2, 2015
Enhancing cancer clonality analysis with integrative genomicsErich A Peterson, Michael A Bauer, Shweta S Chavan, et al.
Leukemia|February 23, 2018
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?Charlotte Pawlyn, Andrea Loehr, Cody Ashby, et al.
Neoplasia (New York, N.Y.)|April 7, 2022
Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destructionHayley M Sabol, Tânia Amorim, Cody Ashby, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
Haematologica|February 22, 2024
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myelomaHayley M Sabol, Cody Ashby, Manish Adhikari, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
European Journal of Haematology|October 27, 2020
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNAShayu Deshpande, Ruslana G Tytarenko, Yan Wang, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Haematologica|February 22, 2020
Differential RNA splicing as a potentially important driver mechanism in multiple myelomaMichael A Bauer, Cody Ashby, Christopher Wardell, et al.
Life Science Alliance|February 24, 2026
Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulationNoemi Garcia Garcia, Thanh Ha Vy Nguyen, Dane Richey, et al.
BMC Bioinformatics|October 2, 2015
Enhancing cancer clonality analysis with integrative genomicsErich A Peterson, Michael A Bauer, Shweta S Chavan, et al.
Leukemia|February 23, 2018
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?Charlotte Pawlyn, Andrea Loehr, Cody Ashby, et al.
Neoplasia (New York, N.Y.)|April 7, 2022
Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destructionHayley M Sabol, Tânia Amorim, Cody Ashby, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
Haematologica|February 22, 2024
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myelomaHayley M Sabol, Cody Ashby, Manish Adhikari, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
European Journal of Haematology|October 27, 2020
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNAShayu Deshpande, Ruslana G Tytarenko, Yan Wang, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Pageof 6